altimmune
present
two
upcoming
virtual
investor
conferences
gaithersburg
globe
newswire
altimmune
nasdaq
alt
biopharmaceutical
company
advancing
proprietary
intranasal
vaccines
peptide
therapeutics
liver
disease
today
announced
management
present
following
upcoming
virtual
investor
conferences
wainwright
hepatitis
b
virus
hbv
virtual
conference
tuesday
october
pm
edt
riley
securities
liver
disease
symposium
thursday
october
wainwright
hbv
presentation
webcast
accessed
visiting
investor
relations
section
company
website
events
presentations
altimmune
altimmune
clinical
stage
biopharmaceutical
company
focused
developing
intranasal
vaccines
immune
modulating
therapies
treatments
liver
disease
company
diverse
pipeline
includes
proprietary
intranasal
vaccines
anthrax
influenza
intranasal
immune
modulating
therapeutic
next
generation
peptide
therapeutics
nash
chronic
hepatitis
b
heptcell
information
altimmune
please
visit
investor
contacts
